Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis

. 2018 Jan ; 109 (1) : 174-181. [epub] 20171109

Jazyk angličtina Země Velká Británie, Anglie Médium print-electronic

Typ dokumentu klinické zkoušky, fáze III, časopisecké články, multicentrická studie, randomizované kontrolované studie

Perzistentní odkaz   https://www.medvik.cz/link/pmid29055056

In the phase III RADIANT-4 study, everolimus improved median progression-free survival (PFS) by 7.1 months in patients with advanced, progressive, well-differentiated (grade 1 or grade 2), non-functional lung or gastrointestinal neuroendocrine tumors (NETs) vs placebo (hazard ratio, 0.48; 95% confidence interval [CI], 0.35-0.67; P < .00001). This exploratory analysis reports the outcomes of the subgroup of patients with lung NETs. In RADIANT-4, patients were randomized (2:1) to everolimus 10 mg/d or placebo, both with best supportive care. This is a post hoc analysis of the lung subgroup with PFS, by central radiology review, as the primary endpoint; secondary endpoints included objective response rate and safety measures. Ninety of the 302 patients enrolled in the study had primary lung NET (everolimus, n = 63; placebo, n = 27). Median PFS (95% CI) by central review was 9.2 (6.8-10.9) months in the everolimus arm vs 3.6 (1.9-5.1) months in the placebo arm (hazard ratio, 0.50; 95% CI, 0.28-0.88). More patients who received everolimus (58%) experienced tumor shrinkage compared with placebo (13%). Most frequently reported (≥5% incidence) grade 3-4 drug-related adverse events (everolimus vs. placebo) included stomatitis (11% vs. 0%), hyperglycemia (10% vs. 0%), and any infections (8% vs. 0%). In patients with advanced, progressive, well-differentiated, non-functional lung NET, treatment with everolimus was associated with a median PFS improvement of 5.6 months, with a safety profile similar to that of the overall RADIANT-4 cohort. These results support the use of everolimus in patients with advanced, non-functional lung NET. The trial is registered with ClinicalTrials.gov (no. NCT01524783).

Zobrazit více v PubMed

Yao JC, Hassan M, Phan A, PubMed

Detterbeck FC. Clinical presentation and evaluation of neuroendocrine tumors of the lung. Thorac Surg Clin. 2014;24:267–276. PubMed

Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(Suppl 1):3–7. PubMed

Rekhtman N. Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med. 2010;134:1628–1638. PubMed

Oberg K, Hellman P, Ferolla P, Papotti M, Group EGW. Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2012;23(Suppl 7):vii120–vii123. PubMed

Granberg D. Neuroendocrine tumors of the lung In:Yalcin S, Öberg K, eds. Neuroendocrine Tumors: Diagnosis and Management. Berlin, Heidelberg:Springer‐Verlag;2015:143–164.

Filosso PL, Ferolla P, Guerrera F, PubMed PMC

Krug LM, Kris MG, Rosenzweig K,

Pavel M, O'Toole D, Costa F, PubMed

Filosso PL, Ruffini E, Oliaro A, Papalia E, Donati G, Rena O. Long‐term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide. Eur J Cardiothorac Surg. 2002;21:913–917. PubMed

Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller‐Brand J. The clinical value of [90Y‐DOTA]‐D‐Phe1‐Tyr3‐octreotide (90Y‐DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001;12:941–945. PubMed

Mariniello A, Bodei L, Tinelli C, PubMed

Kulke MH, Lenz HJ, Meropol NJ, PubMed

Grande E, Capdevila J, Castellano D, PubMed

Yao JC, Phan A, Hoff PM, PubMed

Brizzi MP, Berruti A, Ferrero A, PubMed PMC

Bajetta E, Catena L, Procopio G, PubMed

Ekeblad S, Sundin A, Janson ET, PubMed

Fazio N, Granberg D, Grossman A, PubMed

Yao JC, Lombard‐Bohas C, Baudin E, PubMed PMC

Yao JC, Shah MH, Ito T, PubMed PMC

Yao JC, Fazio N, Singh S, PubMed PMC

Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas. 2010;39:707–712. PubMed

Rindi G, Arnold R, Bosman FT,

Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine tumors of the lung: current challenges and advances in the diagnosis and management of well‐differentiated disease. J Thorac Oncol. 2017;12:425–436. PubMed

Pelosi GFA, Cossa M, PubMed

Ferolla P, Brizzi MP, Meyer T,

Yao JC, Fazio N, Singh S,

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01524783

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace